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A
 
successful ISPOR Inaugural European Con-
ference held 10–12 December 1998 in Col-
ogne, Germany, boasted over 370 participants
from academia, the healthcare industry, consult-
ing, healthcare providers, and government. Regis-
tration exceeded expectations; in fact, so many ex-
citing abstracts were submitted for consideration
that the conference was extended by a half day to
accommodate the greater than expected number
of presentations. While many conference partici-
pants came from the United States and Canada
(about 60), the majority attended from European
countries (over 300), and some made the long
journey from Russia, Asia, or Australia (14).
Thursday morning activities included stimulat-
ing and well-attended preconference ISPOR short
courses covering Pharmacoeconomics, Decision
Analysis in Health Care, Meta-analysis and Other
Statistical Methods, and Quality-of-Life Instru-
ments.
In the afternoon, welcoming remarks and pre-
sentation of conference objectives were made by
Program Committee members: Peter Davey of the
University of Dundee, Scotland; Jonathan Cooke
of South Manchester University Hospitals, En-
gland; and Karl Lauterbach and Thomas Kur-
scheid, both of the Institute for Health Economics
at the University of Cologne, Germany.
Following this introduction, Bernard Genesté of
Rhône-Poulenc Rorer, France, moderated a work-
shop on Presenting Pharmacoeconomic Informa-
tion to European Policy-makers, where the speak-
ers were Peter Davey, Karl Lauterbach, and Thomas
Kurscheid. At the same time, three concurrent po-
dium presentation sessions took place on outcomes
research issues and economic and outcomes study
results. Oliver Mast of Bayer AG, Germany, mod-
erated presentations on Cancer Research; Jonathan
Cooke moderated those on Neurologic and Gas-
tric Disorders; and Koen Torfs of Janssen Pharma-
ceutica, Belgium, was moderator of talks given on
Pulmonary Disorders and Infectious Disease.
On Friday morning, Peter Davey moderated the
First General Session, which comprised reports
and discussion about Developing Consensus on
Pharmacoeconomic Methodology. Joel Hay of the
University of Southern California summarized the
discussions and recommendations of the Method-
ology Advisory Panels (using Clinical Studies,
Modeling, and Databases for Pharmacoeconomic
Research) from the ISPOR Pharmacoeconomics
Consensus Development Conference in February
1998. This was followed by a Summary Report of
the HARMET European Commission Project—
Harmonization of Methodology for Economic
Evaluation of Health Care Technologies in the Eu-
ropean Union—given by Joan Rovira of SOIKOS,
Department of Economics at the University of
Barcelona, Spain. Matthias Graf von Schulen-
burg of the Centre for Health Economics and
Health System at the University of Hannover,
Germany, followed with a Summary Report of
the EUROMET European Commission Project on
Health Care Measurements and Indicators. The
session ended with a lively panel discussion of
key questions in pharmacoeconomic methodology.
Panelists included Jonathan Cooke; Michael Drum-
mond of the Centre for Health Economics at the
University of York, England; Livio Garattini of
the Centre for Health Economics at the Institute
for Pharmacological Research at Ranica, Italy;
Bengt Jönsson of the Stockholm School of Eco-
nomics, Sweden; Karl Lauterbach; and Frank Peys
of the Belgian Institute for Health Economics, Bel-
gium.
The Second General Session on Friday after-
noon, Using Evidence-Based Medicine to Deliver
Cost-Effective Health Care, focused on cardiovas-
cular disease. Karl Lauterbach discussed Contro-
versies with Lipid-lowering Agents, and Ulrich
Keil, from the Institute of Epidemiology and So-
cial Medicine at the University of Münster, Ger-
many, discussed a nine-country survey on cardio-
vascular risk factors.
This session was followed by simultaneous con-
tributed podium presentations of original studies
in economic and outcomes research. Topics in-
cluded Cardiovascular Disease, moderated by
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Thomas Kurscheid; Mental Health, moderated by
Charlotte McMillan of Wyeth-Ayerst Research in
France; and Diabetes and Infectious Disease, mod-
erated by Diana Brixner of Novartis Pharmaceuti-
cals, United States.
On Friday evening, a keynote presentation was
made by Professor Gerhard Krueger, Dean, Col-
ogne University Medical School, speaking on the
crucial subject of “Why Should the Dean of a
Medical School Be Concerned About Managed
Care?” Robert Epstein of Merck-Medco Managed
Care, United States, and President of ISPOR then
spoke of the growth of ISPOR and those chal-
lenges that lie ahead.
The meeting ended on Saturday with the Fourth
General Session, Using Disease Management to
Deliver Cost-Effective Health Care, with a focus
on diabetes, moderated by Karl Lauterbach. The
first speaker, Gregory Gilmet of Quality and Out-
comes Research, Blue Care Network of Michigan,
United States, described his organization’s Data-
Driven Diabetes Disease Management program, a
prototype in this field. Andrew Morris, MEMO,
Ninewells Hospital and Medical School, Dundee
Teaching Hospitals, Scotland, finished the session
with his talk, Working at the Population Level:
The Future of Diabetes Management.
Two sessions of contributed workshops were
fitted into the busy program schedule with 13 pre-
sentations in all. These followed the pattern al-
ready well established at the annual ISPOR meet-
ings, with each workshop being presented twice,
back-to-back, to allow each conference participant
to attend more than one workshop at each ses-
sion. Presentations were relevant to one of four
themes: Decision Support Systems and Models,
Guidelines and Standards, Quality of Life Assess-
ment, or Study Methods.
Sixty contributed poster presentations offered
original research findings and methodological de-
velopments over the 3 days of the meeting in the
therapeutic domains of Cancer and AIDS, Cardio-
vascular Disease, Gastrointestinal and Urinary Tract
Disorders, Diabetes, Infectious Disease, Mental
Health and Neurologic Disorders, and Pulmonary
and Arthritic Disorders, as well as Pharmacoeco-
nomic Methods and Cost of Care Studies.
Exhibitors from around the world provided
contract research, software, database, and scien-
tific information.
The conference was an auspicious opening for
ISPOR’s rapidly growing European presence. The
conference admirably fulfilled ISPOR’s vision of
“translating science into practice” for people of
many diverse languages and cultures. The second
ISPOR European conference will be held in Edin-
burgh, Scotland, 10–13 November 1999 (see www.
ispor.org for further details).
May it be as exciting and educational as the
first European meeting!
